Zydus receives final approval from USFDA and 180 days shared exclusivity for Brivaracetam Tablets
Brivaracetam is indicated for the treatment of partial-onset seizures in patients 4 years of age and older.
Brivaracetam is indicated for the treatment of partial-onset seizures in patients 4 years of age and older.
The inspection concluded with no observation (FDA-483) issued.
Amantadine Extended-Release capsules had annual sales of US $2.7 million in the United States according to IQVIA data
Mirabegron is indicated for the treatment of overactive bladder (OAB) with symptoms of urinary incontinence, urgency, and frequency
Department and Industry Associations to organize 3 days National Level Expo on Indian Medical Devices Sector at Pragati Maidan, New Delhi between 9-11 Dec 2022, first of its kind expo in India
The booster vaccination trial is still ongoing and further data will provide more information around safety and efficacy.
Mirabegron Extended-Release Tablets, 25 mg and 50 mg, had estimated annual sales of US $2.4 billion in US
Sildenafil for Oral Suspension (RLD Revatio) had estimated annual sales of US $64 million in the US
The consideration includes Rs. 115 crore (on the date of signing) of cash and cash equivalents in the acquired business indicating an Enterprise Value of Rs. 1,885 crore
Subscribe To Our Newsletter & Stay Updated